Genoptix Inc. now offers three tests to help doctors better prescribe medicines that use the immune system to fight cancers with solid tumors.
The three options are a PD-L1 22C3 pharmDx companion diagnostic test, a microsatellite instability (MSI) test and a DNA mismatch repair test, according to a news release. The PD-L1 immunohistochemical 22C3 pharmDx test finds the PD-L1 protein in non-small cell lung cancer. That test became the first that the U.S. Food and Drug Administration allowed to determine who out of those battling non-small cell lung cancer could use the medication Keytruda.
The FDA says tumors with high levels of MSI and mismatch repair deficient tumors have irregular components that inhibit DNA from being mended in cells. These kinds of tumors usually form in colorectal, endometrial and gastrointestinal cancers, but they can also form in breast, prostate, thyroid gland and other cancers. Almost 5 percent of patients with colorectal cancer that has spread are MSI-High or mismatch repair deficient tumors.
The new tests are part of Genoptix's plan to help doctors get information that they can use to plan correct medications for each of their patients battling cancer.